A phase I study of anti-PD-L1 antibody, ZKAB001 in China

Trial Profile

A phase I study of anti-PD-L1 antibody, ZKAB001 in China

Phase of Trial: Phase I

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs ZKAB-001 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Lees Pharmaceutical Holdings
  • Most Recent Events

    • 28 Mar 2018 Status changed from planning to recruiting, according to a Sorrento Therapeutics media release.
    • 22 Mar 2018 According to Lee's Pharmaceutical Holdings Limited website, the Company has received approval to proceed with the clinical trials for ZKAB001. Clinical data from this trial is expected to be available by the end of 2019, and positive results could lead to conditional approval of the antibody prior to a confirmatory Phase III study. Link: http://www.leespharm.com/file/investor/LTN20180322470.pdf
    • 22 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top